- Johnson & Johnson sued the Biden administration over Medicare’s new powers to slash drug prices, making it the third pharmaceutical company to challenge the controversial provision of the Inflation Reduction Act.
- The lawsuit filed in federal district court in New Jersey argues the Medicare negotiations violate the First and Fifth Amendments of the U.S. Constitution.
- Earlier suits brought separately by Merck and Bristol Myers Squibb, as well as by the U.S. Chamber of Commerce and PhRMA, the pharmaceutical industry’s largest lobbying group, made similar arguments.
Read More at cnbc.com
- Pauli has wrestled with the eating disorder anorexia for decades; she says she has had a warped relationship with her body since age 8.
- "Every day is hell," she said. "I'm so tired. I'm done. I've tried everything. I feel like I've lived my life."
- An expansion of the criteria for medically assisted death that comes into force in March 2024 will allow Canadians like Pauli, whose sole underlying condition is mental illness, to choose medically assisted death.
Read More at reuters.com
- Causaly, a London startup that has built an AI platform to help researchers accelerate the development and testing of drugs, has raised $60 million, a Series B that will be going toward R&D and to continue building out its team.
- CEO Kiachopoulos estimated that the use of Causaly’s platform can reduce the 10-15 years that it might typically take to take an idea from target to the end of trials, down to around “several” years.
Read More at techcrunch.com
- Eisai and Biogen's Leqembi won a coveted standard approval nod from the U.S. FDA on Thursday, the first Alzheimer's treatment to achieve that goal, clearing the way for wider insurance coverage of the drug.
- A committee of external advisers to the FDA recently recommended traditional approval of the drug after an agency staff report concluded it offered a meaningful benefit to patients and said safety concerns could likely be managed.
Read More at reuters.com
- Moderna struck a deal with Chinese officials to research, develop and manufacture messenger RNA medicines in the country, despite rising tensions between the U.S. and China.
- The Massachusetts-based biotech company will develop those drugs “exclusively for the Chinese people,” a spokesperson told CNBC.
- Moderna is trying to capitalize on the success of its Covid vaccine, which uses a platform called mRNA to teach human cells to produce an immune response against a virus.
Read More at cnbc.com
